Logo image of VXRT

VAXART INC (VXRT) Stock Fundamental Analysis

NASDAQ:VXRT - Nasdaq - US92243A2006 - Common Stock - Currency: USD

0.614  +0.02 (+3.07%)

After market: 0.61 0 (-0.65%)

Fundamental Rating

2

VXRT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. Both the profitability and financial health of VXRT have multiple concerns. VXRT shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VXRT has reported negative net income.
VXRT had a negative operating cash flow in the past year.
In the past 5 years VXRT always reported negative net income.
In the past 5 years VXRT always reported negative operating cash flow.
VXRT Yearly Net Income VS EBIT VS OCF VS FCFVXRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -36.66%, VXRT perfoms like the industry average, outperforming 59.43% of the companies in the same industry.
Looking at the Return On Equity, with a value of -127.41%, VXRT is in line with its industry, outperforming 40.40% of the companies in the same industry.
Industry RankSector Rank
ROA -36.66%
ROE -127.41%
ROIC N/A
ROA(3y)-66.71%
ROA(5y)-50.62%
ROE(3y)-117.91%
ROE(5y)-83.49%
ROIC(3y)N/A
ROIC(5y)N/A
VXRT Yearly ROA, ROE, ROICVXRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

VXRT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VXRT Yearly Profit, Operating, Gross MarginsVXRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

1

2. Health

2.1 Basic Checks

VXRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
VXRT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, VXRT has more shares outstanding
VXRT has a better debt/assets ratio than last year.
VXRT Yearly Shares OutstandingVXRT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
VXRT Yearly Total Debt VS Total AssetsVXRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

VXRT has an Altman-Z score of -4.78. This is a bad value and indicates that VXRT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of VXRT (-4.78) is comparable to the rest of the industry.
VXRT has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
VXRT has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: VXRT outperforms 41.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -4.78
ROIC/WACCN/A
WACC8.82%
VXRT Yearly LT Debt VS Equity VS FCFVXRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 0.64 indicates that VXRT may have some problems paying its short term obligations.
With a Current ratio value of 0.64, VXRT is not doing good in the industry: 91.92% of the companies in the same industry are doing better.
VXRT has a Quick Ratio of 0.64. This is a bad value and indicates that VXRT is not financially healthy enough and could expect problems in meeting its short term obligations.
VXRT's Quick ratio of 0.64 is on the low side compared to the rest of the industry. VXRT is outperformed by 91.38% of its industry peers.
Industry RankSector Rank
Current Ratio 0.64
Quick Ratio 0.64
VXRT Yearly Current Assets VS Current LiabilitesVXRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.06% over the past year.
VXRT shows a strong growth in Revenue. In the last year, the Revenue has grown by 433.37%.
Measured over the past years, VXRT shows a very strong growth in Revenue. The Revenue has been growing by 23.72% on average per year.
EPS 1Y (TTM)49.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)433.37%
Revenue growth 3Y217.11%
Revenue growth 5Y23.72%
Sales Q2Q%857.18%

3.2 Future

Based on estimates for the next years, VXRT will show a small growth in Earnings Per Share. The EPS will grow by 0.50% on average per year.
Based on estimates for the next years, VXRT will show a very strong growth in Revenue. The Revenue will grow by 51.49% on average per year.
EPS Next Y12.8%
EPS Next 2Y-12.96%
EPS Next 3Y1.93%
EPS Next 5Y0.5%
Revenue Next Year-6.04%
Revenue Next 2Y-51.77%
Revenue Next 3Y-59.12%
Revenue Next 5Y51.49%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VXRT Yearly Revenue VS EstimatesVXRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M 250M
VXRT Yearly EPS VS EstimatesVXRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VXRT. In the last year negative earnings were reported.
Also next year VXRT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VXRT Price Earnings VS Forward Price EarningsVXRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VXRT Per share dataVXRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.96%
EPS Next 3Y1.93%

More info and screens

0

5. Dividend

5.1 Amount

VXRT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VAXART INC

NASDAQ:VXRT (6/18/2025, 8:00:01 PM)

After market: 0.61 0 (-0.65%)

0.614

+0.02 (+3.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-06 2025-08-06
Inst Owners12.07%
Inst Owner Change-23.19%
Ins Owners1.03%
Ins Owner Change51.51%
Market Cap140.13M
Analysts86.67
Price Target4.76 (675.24%)
Short Float %6.52%
Short Ratio3.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.06%
Min EPS beat(2)31.15%
Max EPS beat(2)50.98%
EPS beat(4)3
Avg EPS beat(4)-26.88%
Min EPS beat(4)-230.84%
Max EPS beat(4)50.98%
EPS beat(8)7
Avg EPS beat(8)-4.36%
EPS beat(12)10
Avg EPS beat(12)-1.05%
EPS beat(16)13
Avg EPS beat(16)-0.9%
Revenue beat(2)1
Avg Revenue beat(2)43%
Min Revenue beat(2)-28.31%
Max Revenue beat(2)114.31%
Revenue beat(4)3
Avg Revenue beat(4)1682.62%
Min Revenue beat(4)-28.31%
Max Revenue beat(4)6175.49%
Revenue beat(8)7
Avg Revenue beat(8)1313.72%
Revenue beat(12)7
Avg Revenue beat(12)849.62%
Revenue beat(16)7
Avg Revenue beat(16)625.02%
PT rev (1m)0%
PT rev (3m)-3.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)26.18%
EPS NY rev (1m)0%
EPS NY rev (3m)23.71%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)204.9%
Revenue NY rev (3m)37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.96
P/FCF N/A
P/OCF N/A
P/B 3.07
P/tB 3.71
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.21
BVpS0.2
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.66%
ROE -127.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.71%
ROA(5y)-50.62%
ROE(3y)-117.91%
ROE(5y)-83.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.2%
Cap/Sales 1.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.64
Quick Ratio 0.64
Altman-Z -4.78
F-Score5
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)64.4%
Cap/Depr(5y)72.15%
Cap/Sales(3y)3209.1%
Cap/Sales(5y)2046.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y12.8%
EPS Next 2Y-12.96%
EPS Next 3Y1.93%
EPS Next 5Y0.5%
Revenue 1Y (TTM)433.37%
Revenue growth 3Y217.11%
Revenue growth 5Y23.72%
Sales Q2Q%857.18%
Revenue Next Year-6.04%
Revenue Next 2Y-51.77%
Revenue Next 3Y-59.12%
Revenue Next 5Y51.49%
EBIT growth 1Y30.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.76%
OCF growth 3YN/A
OCF growth 5YN/A